Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLCA. E. Lisberg,B. Liu,R. Salehi-Rad,J. M. Lee,L. Tran,K. Krysan,R. Lim,C. Dumitras,Z. Jiang,F. Abtin,R. Suh,S. Genshaft,S. Oh,G. A. Fishbein, C. M. O'Higgins, D. Greenwald,J. W. Goldman,D. Elashoff,E. B. Garon,S. DubinettANNALS OF ONCOLOGY（2022）引用 0|浏览5暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
